Personal Information:

Name: Yeganeh Talebkhan Garoosi

Current Position: PhD, Associate Professor, Faculty member of the Medical Biotechnology Department.

Address:

Biotechnology Research Center, Pasteur Institute of Iran, Pasteur Blvd., Tehran, Iran 14136

Tel: +9821 66953311-9

Fax: +9821 66480780

E-MAIL: talebkhan@pasteur.ac.ir, ytgaroosi@gmail.com.

Education:

2010-2011, Post Doc, Medical Biotechnology, Pasteur Institute of Iran, Tehran, Iran

2003-2010, PhD, Medical Biotechnology, Pasteur Institute of Iran, Tehran, Iran

2000-2002, MSc, Medical Biotechnology, Tarbiat Modarres University, Tehran, Iran

1995-1999, BSc, Molecular and Cellular Biology (Microbiology), Alzahra University, Tehran, Iran

Skills:

Microbiological skills:

- Culturing and isolation of pathogenic bacterium, Helicobacter pylori
- Identity confirmation of isolated bacteria through microscopic examination, gram staining, and biochemical tests.
- Genotyping of virulence markers of H. pylori by PCR.

Molecular (DNA/Protein) Techniques:

- Primer designing
- PCR, RT-PCR, Real Time PCR (qPCR)
- Molecular Cloning
- Recombinant Gene Expression
- SDS-PAGE, Two-dimensional gel electrophoresis
- FPLC Protein purification

Serological techniques:

- Western Blotting, Dot Blotting
- ELISA
- Multiplex ELISA

Cell culture experience:

- Mammalian cell culture

Statistical analysis:

- SPSS software

Research Experiences (Grants):

- **International grants:**

1. Identification of biomarkers for early detection of gastric cancer through genomics and proteomics approach (as a MSc research associate).

   (Funded by: Islamic Development Bank, Saudi Arabia. 2008)

2. Etiology of gastric cancer in Iran (as a MSc research associate).

   (Co-Funded by: Karolinska Institute & Iranian Ministry of Health. 2002)

3. Antigenic characterization of Iranian *Helicobacter pylori* strains (as a BSc research assistant).

   (Co-Funded by: Iran-Austria Collaborative Projects. 2000)

National grants:

- Development of SP2/0 stable mammalian cell line producing biosimilar Golimumab anti-TNF alpha monoclonal antibody (as principal investigator).
- Development of engineered *E. coli* cells producing Fab antibody fragment of Certolizumab pegol (as principal investigator).
  (Funded by: Technological development department of presidential office, Tehran, Iran, 2016)
- Production and optimization of recombinant Fab fragment of Ranibizumab (Lucentis^{TM}) in biosimilar format (as a PhD research associate).
  (*Funded by: National Biotechnology Network, Tehran, Iran. 2013)*

- Development of serologic kit for diagnosis of *Helicobacter pylori* infection (as a MSc research associate).

  (*Funded by: National Biotechnology Network, Tehran, Iran. 2002)*

Pasteur Institute of Iran:

- Cloning, expression and purification of protein fragments from cytotoxin-associated gene (*cagA*) from Iranian isolated *Helicobacter pylori* strains for serological screening purposes (as a MSc research associate).

  (Funded by: Pasteur Institute of Iran, Tehran, Iran. 2007)
- Design and development of an ELISA kit for the detection of anti-Helicobacter pylori IgA antibodies using native Hp antigens (as a PhD research associate).

  (Funded by: Pasteur Institute of Iran, Tehran, Iran. 2010)
- Evaluating the association of *SEMA4A* polymorphism and AMD disease among Iranian patients (as a PhD research associate).

  (Funded by: Pasteur Institute of Iran, Tehran, Iran. 2012).
- Design and construction of a vector for recombinant protein expression in the yeast *Hansenula polymorpha* and expression of Granulocyte colony-stimulating factor (GCSF) as a candidate protein (as principal investigator).

  (Funded by: Pasteur Institute of Iran, Tehran, Iran. 2013).
- Design and development of a construct for the expression of VEGF-Trap in eukaryotic host CHO and nonpathogenic parasite *Leishmania tarentolae* (as a PhD research associate).

  (Funded by: Pasteur Institute of Iran, Tehran, Iran. 2013).
- Tracking intercellular mechanisms involved in the solubility increase of anti-VEGF Fab fragment expressed in a fed-batch cultivation mode in *E. coli* (As principal investigator).

  (Funded by: Pasteur Institute of Iran, Tehran, Iran, 2015)
- Production of an Antibody fragment (V2L2) with improved half-life against PcrV protein of *Pseudomonas aeruginosa* in mammalian HEK and prokaryotic *E. coli* host (as principal investigator)

  (*Funded by: Pasteur Institute of Iran, Tehran, Iran, 2016).*
- Expression of α-luffin immunotoxin conjugated to anti-HER2 scFv in *E. coli* cell and study of its inhibitory effects on breast cancer cell lines (as principal investigator)

(Co-Funded by: Pasteur Institute of Iran, Tehran, Iran (2017) & Iran National Science Foundation, 2018).

- Site-specific integration of GFP reporter gene in CHO cells mediated by CRISPR/Cas9 system (as a PhD research associate).
  (*Funded by: Pasteur Institute of Iran, Tehran, Iran, 2018).*
- Production of human recombinant soluble angiotensin-converting enzyme 2 (hrsACE2) in CHO mammalian cells (as a PhD research associate).
  (*Funded by: Pasteur Institute of Iran, Tehran, Iran, 2021).*
- Preparation and characterization of niosomal nano-carriers containing Oxaliplatin targeted by Cetuximab-derived scFv and evaluation of their in vitro cytotoxicity on human colorectal cancer cell line (as principal investigator)
  (*Co-funded by: Pasteur Institute of Iran, Tehran, Iran & Tehran University of Medical Sciences, 2021).*
- Expression and characterization of single-chain antibody fragments against TNF-α and IL-6 receptor alone and together as a bispecific antibody in *E. coli* (as principal investigator).
  (*Funded by: Pasteur Institute of Iran, Tehran, Iran, 2021).*
- Evaluation of DHODH-targeted drug candidates in inhibition of Helicobacter pylori growth and examination of proof of concept with reversal assays and DHODH over-expression in H. pylori (as principal investigator)
  (*Funded by: Pasteur Institute of Iran, Tehran, Iran, 2021).*
- Design and expression of multimeric recombinant protein A and evaluation of its efficiency in the purification of IgG molecules. (as principal investigator)
  (*Funded by: Pasteur Institute of Iran, Tehran, Iran, 2024).*

Teaching experiences/courses:

Pasteur Institute of Iran (as a lecturer): 2012- present

- Molecular genetics and genetic engineering of bacteria
- Advanced molecular biology
- Protein engineering (enzyme engineering)
- Chemistry of proteins
- Quality control of pharmaceuticals

Azad University (as a lecturer): 2016- present

- DNA structure and Replication
- Introduction to Biotechnology
- Genetic engineering of prokaryotes
- Pharmaceutical Biotechnology

Publications:

Chapter of a Books:

- Marjan Mohammadi, Samaneh Saberi Kashani, **Yeganeh Talebkhan Garoosi**, Sahar Jahangiri Tazehkand. In vivo measurement of Helicobacter pylori infection: Culture, Urease test, Serology, Stool-based PCR, Chapter 25. In: Houghton J, ed. ***Methods Mol Biol***: Helicobacter pylori Protocols. Totowa, NJ: Humana Press, **2012**; 921: 239-256.

Papers:

1. Heravi M, Damough Sh, Mafakher L, **Talebkhan Y**, Nematollahi L, Ghazizadeh L, Ajdari S. A novel bispecific antibody targeting TNF-α and IL-6 receptor as a potent immunotherapeutic agent for inflammation. ***Appl Microbiol Biotechnol;*** Accepted.
2. Development of Experimental Platforms to Assess Helicobacter pylori HopQ Interaction with Host CEACAM Molecules. Shans N, Esmaeili M, Abraheh K, Asadi Hanjani N, Farrokhi M, Sardarpour N, **Talebkhan Y**, Kazemi-Lomedasht F, Mirabzadeh E, Mohammadi M. ***Iran Biomed J*. 2025;** 29(3):138-148. doi: 10.61186/ibj.5043.
3. Ligand multimerization effects on binding efficiency of Protein L affinity chromatography resins. Nikzad J, Komijani S, Kalantari Khandani K, **Talebkhan Y**, Zandi F, Adeli A. ***Protein Expr Purif*. 2025;** 235: 106790. doi.org/10.1016/j.pep.2025.106790.
4. Cetuximab scFv-Modified 5-FU Loaded Chitosan Nanoparticles: "A Novel Therapeutic Platform". Jalalvand M, Esmaeili F, Falahzadeh K, Mazloumi MA, Shahsavari Gh, Bayat E, Zandsalimi F, **Talebkhan Y**, Nematollahi L, Negahdari B. ***Curr Pharm Biotechnol*. 2024;** doi: 10.2174/0113892010340791241025033549.
5. Optimization of culture condition for improved Follicle-Stimulating hormone production by CHO-DG44 cells in serum-free medium. Ghobadian H, Roshanzamir Kh, Kouhi Abdolabadi MH, Ostadi H, Zati Keikha R, Dolatkhah Baghan M, **Talebkhan Y**, Torkashvand F. ***Iranian***

***Biomedical Journal*. 2024;** 28 (5&6): 3-3.

6. Optimization of culture condition for Spodoptera frugiperda by design of experiment approach and evaluation of its effect on the expression of hemagglutinin protein of influenza virus. Alizadeh F, Aghajani H, Mahboudi F, **Talebkhan Y**, Arefian E, Samavat S, Raufi R. ***PLOS ONE*. 2024;** 19(8):e0308547.
7. Formulation, Characterization, and Potential Therapeutic Implications of Encapsulated Recombinant Alpha-Luffin in Niosomes. Abedi Joni H, Esmaeili F, Landi B, Bayat E, Bakhshandeh H, **Talebkhan Y**, Barkhordari F, Sadeghi S, Nematollahi L, Negahdari B. ***Curr Pharm Biotechnol.* 2024;** 10.2174/0113892010316435240806053230.
8. Induction of heat shock protein expression in SP2/0 transgenic cells and its effect on the production of monoclonal antibodies. Jaffaraghaei M, Ghafouri H, Vaziri B, Taheri M, Talebkhan Y, Heravi M, Parand M. ***PLOS ONE*; 2024;** 19 (5): e0300702.
9. Specific targeting of zinc tranporter LIV-1 with immunocytokine containing anti-LIV-1 VHH and human IL-2 and evaluation of its in vitro antitumor activity. Dehghan R, Beig Parikhani A, Ahangari Cohan R, Shokrgozar MA, Mirabzadeh E, Ajdari S, Zeinali S, Ghaderi H, **Talebkhan Y**, Behdani M. ***Curr Pharm Design***. **2024**; 30: 868-876.
10. A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic Beig Parikhani A, Dehghan R, **Talebkhan Y**, Bayat E, Biglari A, Shokrgozar MA, Ahangari Cohan R, Mirabzadeh E, Ajdari S, Behdani M. ***AMB Express*. 2024;** 14: 19.
11. Expression, Purification, and Biological Evaluation of XTEN-GCSF in a Neutropenic Rat Model. Yadavar Nikravesh F, Gholami P, Bayat E, **Talebkhan Y**, Mirabzadeh E, Damough Sh, Aghamirza Moghim Aliabadi H, Nematollahi L, Hosseinzadeh Ardakani Y. ***Appl Biochem Biotechnol***. **2024**; 196 (2): 804/820. doi: 10.1007/s12010-023-04522-w.
12. Damough Sh, Bayat E, Oghabi T, Barkhordari F, Esmaeili R, Nematollahi L, **Talebkhan Y**. Recombinant anti-human epidermal growth factor receptor type 2 single chain variable fragment-alpha luffin protein as a putative immunotoxin against human epidermal growth factor receptor type 2-positive breast cancer cells: an experimental research. ***Annals of Medicine and Surgery*. 2023;** 85: 4348-4354.
13. Soluble Expression of Recombinant Human Bone Morphogenetic Protein-7 (rhBMP-7) in Escherichia coli Using SUMO Fusion System. Sadipour G, Dugmehchi A, Talebkhan Y,

Barkhordari F, Mohit E, Nematollahi L. ***Trends Pept Protein Sci***. **2023**; 8 (1): 1-12 (e5)

14. Computational and Experimental Evaluation of Linker Peptides and Thioredoxin Fusion Tag in CD20-rituximab Specific Interactions. Damough Sh, Alizadeh R, Komijani S, Shirin M, Adeli A, Mafakher L, Mahboudi F, **Talebkhan Y.** ***Iran J Pharm Res*****; 2022; 21: e134267.**
15. Computational analysis of fusion protein of anti-HER2 scFv and alpha luffin: A new immunotoxin protein for HER2 positive cancers. Barkhordari F, Rismani E, Tabasinezhad M, Asgari S, Nematollahi N, **Talebkhan Y**. ***Braz J Pharm Sci*****; 2022; 58**.
16. Efficacy and antitumor activity of a mutant type of interleukin 2. Dehghan R, Beig Parokhani A, Zeinali S, Shokrgozar MA, Amanzadeh A, Ajdary S, Ahangari Cohan R, **Talebkhan Y**, Behdani M. ***Sci Rep*****; 2022; 12: 5376.**
17. Human IL-2Rα subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach. Beig Parikhani A, Bagherzadeh K, Dehghan R, Biglari A, Shokrgozar MA, Riazi Rad F, Zeinali S, **Talebkhan Y**, Ajdary S, Ahangari Cohan R, Behdani M. ***PLOS One;*** **2022;** 17 (2): e0264353.
18. Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate. Oghalaie A, Mahboudi F, Rahimi-Jamnani F, Piri-Gavgani S, Kazemi-Lomedasht F, Hassanzadeh Eskafi A, Shahbazzadeh D, Adeli A, **Talebkhan Y**, Behdani M. ***Iran J Basic Med Sci;*** **2022;** 25: 1-7.
19. Extension of human GCSF serum half-life by the fusion of albumin binding domain. Nikravesh FY, Shirkhani S, Bayat E, **Talebkhan Y**, Mirabzadeh E, Sabzalinejad M, Aliabadi HAM, Nematollahi L, Ardakani YH, Sardari S. ***Sci Rep;*** **2022;** 12 (1): 667.
20. Production of an Antibody Fragment (scFv) Targeting PcrV Protein of Pseudomonas aeruginosa in Fed-Batch Cultivation Mode. Karam S, Raigani M, Hassani Afshar S, **Talebkhan Y**, Bayat E, Komijani S, Nematollahi L, Barkhordari F, Shafiee Ardestani M, Davami F. ***IBJ;*** **2021;** 25 (6): 390-398.
21. Induction of immunogenic response in BALB/c mice by live and killed form of recombinant Lactococcus lactis displaying EG95 of Echinococcus granulosus. Ebrahimzadeh F, Shirdast H, Taromchi A, **Talebkhan Y**, Haniloo A, Esmaeilzadeh A, Nedaei K, Mirabzadeh E. ***IBJ;*** **2021;** 25 (4): 284-296.
22. Production of soluble and functional anti-TNF-α Fab' fragment in cytoplasm of *E. coli*:

Investigating the effect of process conditions on cellular biomass and protein yield suing response surface methodology. Talaei A, Mazaheri S, Bayat E, Bakhshandeh B, Sabzalinejad M, Damough Sh, Mahboudi F, Nematollahi L, **Talebkhan Y**. ***Protein J;*** **2021;** 40 (5): 786-798.

23. Characterization of a novel mCH3 conjugated anti-PcrV molecule. Komijani S, Bayat E, Rismani E, Hosseini S, Moazzami R, Nematollahi L, Sardari S, **Talebkhan Y**, Davami F, Barkhordari F, Hosseini F, Jahandar H. ***Sci Rep;*** **2021;** 11: 7154.
24. Anti-Aβ-scFv-loaded polymeric nano-micelles with enhanced plasma stability. Sotoudegan F, Sotoudegan F, **Talebkhan Garoosi Y**, Afshar SH, Barkhordari F, Davami F. ***J Pharm Pharmacol;*** **2021;** XX: 1-13.
25. Optimization of culture conditions for high-level expression of soluble and active tumor necrosis factor-α in *E. coli*. Damough Sh, Sabzalinezhad M, **Talebkhan Y**, Nematollahi L, Bayat E, Torkashvand F, Adeli A, Jahandar H, Barkhordari F, Mahboudi F. ***Protein Expr Purif;*** **2021;** 179 (105805); 1-8.
26. Improvement of Certolizumab Fab' properties by PASylation technology. Mazaheri S, Talebkhan Y, Mahboudi F, Nematollahi L, Ahangari Cohan R, Mirabzadeh Ardakani E, Bayat E, Sabzalinejad M, Sardari S, Torkashvand F. ***Sci Rep;*** **2020**; 10 (1):18464.
27. DARPin Ec1‑LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker. Babaee N, **Talebkhan Garoosi Y**, Karimipoor M, Davami F, Bayat E, Safarpour H, Mahboudi F, Barkhordari F. ***Mol Biol Rep;*** **2020;** 47 (10):7323-7331.
28. Design, expression, purification and evaluation of anti-HER2 scFv. Heydari M, Aliabadi Farahani Z, Bayat E, Damough Sh, Sabzalinezhad M, **Talebkhan Y**. ***Pathobiol Res;*** **2020;** 23 (1): 49-56.
29. The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance. Tabasinezhad M, Omidinia E, **Talebkhan Y**, Omrani MD, Mahboudi F, Ghaedi H, Wenzel W. ***Proteins Structure, Function and Bioinformatics***, **2020**; 88: 3-14.

30. Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches. Tabasinezhad M, **Talebkhan Y**, Wenzel W, Rahimi H, Omidinia E, Mahboudi F. ***Immunol Lett*, 2019**; 212: 106-113.

31. Cloning, expression and characterization of a HER2-alpha luffin fusion protein in Escherichia coli. Barkhordari F, Sohrabi N, Davami F, Mahboudi F, **Talebkhan Y**. ***Preparative Biochem Biotechnol,* 2019**; 49: 759-766.

32. Proteomics investigation of molecular mechanisms affected by EnBase culture system in anti-VEGF fab fragment producing *E. coli* BL21 (DE3). Azarian B, Azimi A, Sepehri M, Samimi Fam V, Rezaie F, **Talebkhan Y**, Khalaj V, Davami F. ***Preparative Biochem Biotechnol,* 2019**; 49: 48-57.

33. A comparative study of the bispecific monoclonal antibody, blinatumomab expression in CHO cells and *E. coli*. Naddafi F, Shirazi FH, **Talebkhan Y**, Tabarzad M, Barkhordari F, Aliabadi Farahani Z, Bayat E, Moazzami R, Mahboudi F, Davami F. ***Preparative Biochem Biotechnol,* 2018**; 48: 961-967.

34. Optimization of EnBase Fed-Batch Cultivation to improve Soluble Fraction Ratio of α-Luffin Ribosome Inactivating Protein. Barkhordari F, Raigani M, **Talebkhan Y**, Mahboudi F, Davami F. ***Iran J Biotech*, 2018**; 16: 49-59.

35. Serum Antibodies against *Helicobacter pylori* Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer. **Talebkhan Y**, Doozbakhshan M, Saberi S, Esmaeili M, Karami N, Mohajerani N, Abdirad A, Eshagh Hosseini M, Nahvijou A, Mohagheghi MA, Mohammadi M. ***Iran Biomed J,* 2017.** 21: 321-329.

36. *Helicobacter pylori* Strains from Duodenal Ulcer Patients Exhibit Mixed babA/B Genotypes with Low Levels of BabA Adhesin and Lewis b Binding. Saberi S, Schmidt A, Eybpoosh S, Esmaili M, **Talebkhan Y**, Mohajerani N, Oghalaie A, Eshagh Hosseini M, Mohagheghi MA, Bugaytova J, Borén T, Mohammadi M. ***Dig Dis Sci,* 2016.** 61 (10): 2868-2877.

37. Expression of granulocyte colony stimulating factor (GCSF) in *Hansenula polymorpha.* **Talebkhan Y,** Samadi T, Samie A, Barkhordari F, Azizi M, Khalaj V, MIrabzadeh E. ***Iran J***

Microbiol, 2016. 8 (1): 21-28.

38. Construction of Bacterial Ghosts for Transfer and Expression of a Chimeric Hepatitis C virus gene in Macrophages. Miri MR, Behzad-Behbahani A, Fardaei M, Farhadi A, **Talebkhan Y**, Mohammadi M, Tayebinia M, Farokhinejad F, Alavi P, Fanian M, Zare F, Saberzade J, Nikouyan N, Okhovat MA, Ranjbaran R, Rafiei Dehbidi G, Naderi S. ***J Microbiol Methods***. ***2015***. 19: 228-232.
39. Distribution of cytokine gene single nucleotide polymorphisms among a multi-ethnic Iranian population. Karimi Kurdistani Z, Saberi S, **Talebkhan Y**, Oghalaie A, Esmaeili M, Mohajerani N, Bababeik M, Hassanpour P, Barani Sh, Farjaddoost A, Ebrahimzadeh F, Trejaut J, Mohammadi M. ***Adv Biomed Res.*** **2015**, 4: 160.
40. Age-Specific Gastric Cancer Risk Indicated by the Combination of Helicobacter pylori Sero-Status and Serum Pepsinogen Levels. Eybpoosh S, **Talebkhan Y**, Saberi S, Esmaeili M, Oghalaie A, Ebrahimzadeh F, Karimi T, Abdirad A, Nahvijou A, Mohagheghi MA, Eshagh Hosseini M, Mohammadi M. **Iran Biomed J. 2015** Jul;19(3):133-42.
41. Cloning and Expression of Human Keratinocyte Growth Factor in *Escherichia coli* for Recombinant Drug Production. Ebrahimzadeh F, **Talebkhan Y**, Mirzahoseini H, Barati G, Saidijam M. **Avicenna J Med Biochem. 2014** Sept; 2 (1): e19002.
42. Seroreactivity to Helicobacter pylori Antigens as a Risk Indicator of Gastric Cancer. Karami N, **Talebkhan Y**, Saberi S, Esmaeili M, Oghalaie A, Abdirad A, Mostafavi E, Hosseini ME, Mohagheghi MA, Mohammadi M. ***Asian Pac J Cancer Prev***. **2013**, 14 (3): 1813-1817.
43. Impact of Methylenetetrahydrofolate Reductase C677T polymorphism on the risk of gastric cancer and its interaction with Helicobacter pylori infection. Saberi S, Zendehdel K, Jahangiri S, **Talebkhan Y**, Abdirad A, Mohajerani N, Bababeik M, Karami N, Esmaili M, Oghalie A, Hassanpour P, Amini N, Mohagheghi MA, Eshagh Hossieni M, Mohammadi M. ***Iranian Biomedical Journal.*** **2012,** 16 (4): 179-184.
44. *Helicobacter pylori* Omp18 and its application in serologic screening of infection. **Talebkhan Y,** Ebrahimzadeh F, Esmaeili M, Zamaninia L, Nahvijou A, Khedmat H, Fereidooni F, Mohagheghi M, Mohammadi M. ***Cur Microbiol.*** **2011,** 62 (1): 325-30 [PMID:

20652254]

45. Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine. **Talebkhan Y**, Bababeik M, Esmaeili M, Oghalaei A, Saberi S, Karimi Z, Afkhami N, Mohammadi M. ***J Microbiol Methods***. **2010;** 82(3): 334-7 [PMID: 20621134]

46. Cooperative genotyping for Helicobacter pylori virulence determinants strengthens the predictive value of gastric cancer risk assessment. Douraghi M, **Talebkhan Y**, Zeraati H, Mohammadi M. ***Dig Liver Dis*. 2010;** 42(9): 662-3 [PMID: 20172771]

47. Interobserver variations in histopathological assessment of gastric pathology. **Talebkhan Y**, Mohammadi M, Rakhshani N, Abdirad A, Fayaz Moughadam K, Fereidooni F. ***Pathology*. 2009**; 41(5):428-32 [PMID: 19900080]

48. Multiple Gene Status in Helicobacter pylori Strains and Risk of Gastric Cancer Development. Douraghi M, **Talebkhan Y**, Zeraati H, Ebrahimzadeh F, Nahvijoo A, Morakabati A, Ghafarpour M, Esmaili M, Bababeik M, Oghalaie A, Rakhshani N, Hosseini ME, Mohagheghi MA, Mohammadi M. ***Digestion*. 2009;** 80(3): 200-207 [PMID: 19752557]

49. Differences in virulence markers between *Helicobacter pylori* strains from Iraq and those from Iran: Potential importance of regional differences in Hp-associated disease. Hussein NR, Mohammadi M, **Talebkhan Y**, Douraghi M, Letley DP, Muhammad MK, Argent RH, Atherton JC. ***J Clin Microbiol*. 2008**; 46(5): 1774-1779 [PMID: 18353934]

50. Advantage of using a home-made ELISA kit for detection of *Helicobacter pylori* infection over commercially imported kits. Mohammadi M, **Talebkhan Y**, Khalili G, Mahboudi F, Massarrat S, Zamaninia L, Oghalaei, A. ***Indian J Med Microbiol*. 2008**; 26(2): 127-131 [PMID: 18445947]

51. *cagA* gene and protein status among Iranian Helicobacter pylori strains. **Talebkhan Y**, Mohammadi M, Mohagheghi MA, Vaziri HR, Eshagh Hosseini M, Mohajerani N, Oghalaei A, Esmaeili M, Zamaninia L. ***Dig Dis Sci*. 2008**; 53(4): 925-932 PMID: [17939043]

52. Detection of *Helicobacter pylori* Infection by Imported IgG ELISA Kits in Comparison with Iranian Home Made Kit. **Talebkhan Y**, Mohammadi M, Khalili G, Haj-sheykholeslami A, Rakhshani N, Mahboudi F, Massarrat S. ***Govaresh*. 2006**; 11(2): 120-125.

53. Cloning and expression of the heterogenic vacuolating cytotoxin from an Iranian *Helicobacter pylori* strain. **Talebkhan Y**, Mahboudi F, Sarrami R, Barkhordari F, Amani M, Mohammadi M. ***Iran J Biotech*. 2004;** 2(2): 123-131.

54. Development of a *Helicobacter pylori* mouse model. Mohammadi M**,** Oghalaei A, Zamaninia L, **Talebkhan Y**, Eshagh Hosseini M. ***Govaresh*. 2004;** 8(4): 147- 152.

55. Vacuolating cytotoxin of *Helicobacter pylori*. **Talebkhan Y,** Mohammadi M**.** ***Iran J Biotech*. 2003;** 1(2): 73-81.

Dissertations (Advisor to):

1. Multimerization of a protein L-derived binding domain for enhancing resin dynamic binding capacity (DBC) used in whole antibody and antibody fragment purification, Jafar Nikzad, **PhD**, Pasteur Institute of Iran, **2025**.
2. *Evaluation of the effect of inducing the expression of heat shock proteins using chemical inducer in SP2/0 cells producing Golimumab monoclonal antibody.* Morteza Jafar Aghaei, **PhD,** Gilan University, **2020.**
3. *In vitro* assessment of antitumoral activity of immunocytokine containing human interleukin-2 and VEGFR2-specific Nanobody. Arezou Parikhani, **PhD**, Pasteur Institute of Iran, **2018**.
4. Targeting of LIV-1 zinc transporter with immunocytokine containing human interleukin-2 and LIV-1 specific VHH and its in vitro antitumor activity evaluation. Rada Asl Dehghan, **PhD**, Pasteur Institute of Iran, **2018.**
5. Development and characterization of single-chain monoclonal antibody against programmed cell death ligand 1 (PD-L1). Akbar Oghalaie, **PhD**, Pasteur Institute of Iran, **2018**.
6. Cloning and Comparison of Expression of a Humanized Anti-TNF-α Antibody Fab Fragment in *E. coli* Hosts. Andisheh Talaei, **MSc**, Tehran University of Medical Sciences, **2018**.
7. Cloning and expression of scFv antibody fragment against Estrogen receptor (ER) in *E. coli* host. Mahboob Navvabi, **MSc,** Islamic Azad University, Pharmaceutical Sciences Branch,

Tehran, **2017.**

8. Surface display of *Echinococcus granulosus* EG95 protein on *Lactococcus lactis* bacteria and evaluation of its immunogenicity in mice. Fatemeh Ebrahimzadeh, **Ph.D**, Zanjan University of Medical Sciences, **2017.**
9. Expression of V2L2 antibody fragment against PcrV protein of Pseudomonas aeruginosa in *E. coli* expression system using SUMO-tag in a fed-batch system. Saba Karam, **Pharm.D,** Tehran University of Medical Sciences, Iran, **2016**.
10. Expression of anti-Alzheimer scFv antibody in *E. coli* expression system using SUMO-tag in a fed-batch system. Sahar Hassani Afshar, **Pharm.D,** Tehran University of Medical Sciences, Iran, **2016**.
11. Cloning and expression of alpha-luffin protein of Luffa cylindrical M. Roem in *E. coli* and tracking its expression profile in batch and fed-batch systems. Farzaneh Barkhordari, **MSc,** Azad University, Tehran, **2015.**
12. Evaluating the expression of *Aspergillus fumigatus* CPS1 homologous gene and developing a genetic construct for abolishing the evaluated gene. Sepideh Farmand Azadeh, **MSc.** Tehran Azad University, Iran, **2013.**
13. Evaluation of Helicobacter pylori virulence factors: cagA, vacA, hom and single-nucleotide polymorphism of IL-8-251 T>A and their association with Gastric Cancer in Tehran. Tannaz Samadi, **MSc,** Jahrom Azad University, Iran, **2013.**
14. Cloning and expression of Keratinocyte growth factor (KGF) in *E. coli*. Fatemeh Ebrahimzadeh, **MSc.** Hamedan University of Medical Sciences, Iran, **2013.**
15. Optimization of TGE (Transient Gene Expression) for Recombinant Protein Production in mammalian cell culture: Bioprocess Scale-up. Farnaz Eghbalpour, **MSc.** Arak Azad University, Iran, **2011.**
16. Cloning & expression of two variable C-terminal fragments of cytotoxin associated gene (*cagA*) from Iranian isolated Hp strains. Nadereh Afkhami, **MSc**. Shahid Beheshti University, Tehran, Iran. **2008.**

17. Sero-epidemiology of *Helicobacter pylori* infection among children referred to two children's hospitals in Tehran. Bahareh Rabti, **Pharm.D,** Azad University, Tehran, Iran. **2007.**

Dissertations (Supervisor):

1. Design, expression, characterization, and evaluation of a bispecific antibody against TNF-α and CD20 in *E. coli* host cells. Shadi Damough, **PhD,** Islamic Azad University, Tehran Medical Sciences, **2025**.
2. Design and expression of a recombinant multimeric form of protein A and evaluation of its efficiency in the purification of the IgG class of antibodies. Shirin Damough, **PhD,** Islamic Azad University, Tehran Medical Sciences, **2024**.
3. Optimization of culture conditions for Spodoptera frugiperda by the design of experiment approach and evaluation of its effect on the expression of hemagglutinin protein of influenza virus. Fatemeh Alizadeh, **PhD,** Pasteur Institute of Iran, **2023.**
4. Expression, characterization, and evaluation of a bispecific antibody against TNF-α and IL-6 receptor in *E. coli* host cells. Mansoureh Heravi, **PhD**, Pasteur Institute of Iran, **2022**.
5. Adaptation of adherent culture of CHO-DG44 cells expressing recombinant human Follitropin Alpha for growth in a serum-free in-house developed medium and evaluation of protein expression level via the selected parameters through Design of Experiment. Hana Ghobadian, **PhD**, Pasteur Institute of Iran, **2022.**
6. Cloning and expression of RANKL protein in *E. coli* host. Maedeh Rabiei. **MSc,** Danesh Alborz University, **2022.**
7. Cloning and expression of tumor necrosis factor alpha (TNF-α) in *E. coli*. Shadi Damough, **MSc,** Islamic Azad University, Tehran Medical Sciences Branch, **2019.**
8. Optimization of expression and pharmacokinetic and pharmacodynamic studies of fusion derivatives of recombinant (ABD-GCSF and XTEN-GCSF) in a Rat model. Fatemeh Nikravesh, **PhD,** Pasteur Institute of Iran, **2018.**
9. Cloning and expression of XTENylated fusion protein of Granulocyte colony stimulating

factor in *E. coli*. Parisa Gholami, **MSc,** Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, **2018.**

10. Cloning and Expression of Granulocyte Colony Stimulating Factor (GCSF) as a fusion to the albumin binding domain in *E. coli*. Samira Shirkhani, **MSc,** Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, **2018.**
11. Design and study of α-luffin immunotoxin conjugated to anti-HER2 scFv and expression in *E. coli* cells with study of its inhibitory effects on breast cancer cell lines. Farzaneh Barkhordari, **PhD,** Payam Noor University, **2018.**
12. Expression of the PASylated form of anti-tumor necrosis factor alpha Fab antibody fragment and evaluation of its physicochemical and biological properties. Somayeh Mazaheri, **PhD,** Pasteur Institute of Iran, **2017.**
13. Expression and purification of anti-HER2 scFv antibody fragment and analysis of its application in the diagnosis of HER2 antigen. Mojdeh Heydari, **MSc,** Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, **2017.**
14. Expression, purification, and investigation of physico-chemical structure and biological activity of antibody fragment (V2L2) against PcrV protein of *Pseudomonas aeruginosa* in *in vitro* conditions. Samira Komijani, **MSc,** Alzahra University, Tehran, **2016.**
15. Cloning and expression of scFv antibody fragment against HER2 protein in *E. coli*. Zahra Aliabadi Farahani, **MSc,** Islamic Azad University, Science and Research Branch, Tehran, **2016.**
16. Survey Effect of Notch siRNA Conjugated to Protamine and Low Molecular Weight Protamine (LMWP) Nanocarriers on Cancer Cells Via Targeted EpCAM Cancer Stem Cells (CSCs) Marker by Ec1 DARPin Scaffold Protein. Nikta Babaei, **PhD,** Pasteur Institute of Iran, **2014.**
17. Cloning and expression of HP-NAP gene in *E. coli* for digestive patient screening. Mohsen Doozbakhshan, **MSc.** Qom Azad University, Iran, **2014.**
18. Cloning and expression of recombinant Granulocyte colony stimulating factor (GCSF) in

Hansenula polymorpha. Armin Samie, **MSc.** Damghan Azad University, Iran, **2014.**